Another recently published study investigated a potential tumor sink effect in the context of CXCR4-directed PET [33], as such a decrease of uptake in normal organs in subjects with increased tumor load has been reported for other theranostic agents, e.g., somatostatin receptor directed radiopharmaceuticals [34]. This evidence concerns the gene CXCR4 and neoplasm.